Guide

FACT-JACIE Accreditation: A Practical Readiness Guide for Cellular Therapy Programmes

FACT (Foundation for the Accreditation of Cellular Therapy) in North America and JACIE (Joint Accreditation Committee ISCT-Europe & EBMT) in Europe jointly maintain the FACT-JACIE International Standards for Hematopoietic Cellular Therapy. The Standards apply across the clinical programme, the apheresis/collection facility and the processing facility, and accreditation is practically required by transplant networks (NMDP, WMDA), payers and most commercial CAR-T sponsors as a condition of treating their products. This guide walks the current 9th edition Standards (2024), the recurring accreditation findings, and a practical path to a defensible cellular therapy programme.

Start free trial Free trial, no credit card, onboard in days, not months.

The 9th edition structure and what changed

FACT-JACIE 9th edition (2024) restructured the Standards across clinical, collection (marrow and apheresis), processing and immune effector cell (IEC) sections, with the IEC overlay covering commercial CAR-T treatment. The 9th edition strengthened cellular therapy product traceability, donor advocacy, and the commercial product handoff at the processing facility. Programmes that achieved 8th edition accreditation must close the delta to the 9th before their next inspection — the delta is non-trivial particularly on IEC, donor advocacy and traceability.

The Quality Management programme and the QM Plan

Section B/C/D 4 require a documented Quality Management programme with an annual QM Plan, defined indicators, audit schedule, and management review. Recurring findings: the QM Plan exists but indicators are not tracked or trended; audits are performed but actions do not close; management review is a single-meeting deliverable rather than an ongoing process. The inspector reads the QM Plan first and the indicator trends second — a thin trend story is a finding regardless of how complete the rest of the file is.

Cellular therapy product traceability and labelling

Standards require complete traceability of cellular therapy products — donor identification, product identification per ISBT 128, chain of custody, chain of identity (particularly for autologous and commercial CAR-T products where mis-identification is fatal), and complete records for at least 10 years post-administration. The 9th edition strengthened chain-of-identity requirements at the commercial CAR-T handoff — the apheresis-to-manufacturer-to-infusion chain must be unbroken and barcode-verified at each handoff.

The Immune Effector Cell (IEC) overlay and commercial CAR-T

The IEC sections cover the clinical treatment of patients with commercial CAR-T and other immune effector cell products. They require defined personnel competency for IEC management, defined ICU/step-down capability for CRS and ICANS, REMS programme integration for FDA-approved products, and the cellular therapy product receipt-handling-infusion chain with full traceability. Programmes new to commercial CAR-T frequently underestimate the IEC documentation requirements.

A 90-day readiness path to FACT-JACIE inspection

Days 1–15: 8th-to-9th delta gap analysis if applicable; QM Plan refresh. Days 16–35: indicator trend story — 12 months of data on the published indicators with trend analysis. Days 36–55: traceability and chain-of-identity end-to-end audit including commercial CAR-T handoff. Days 56–75: IEC overlay readiness if applicable. Days 76–85: internal audit using the published checklist. Days 86–90: management review and pre-inspection rehearsal.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

Chain of Identity

The unbroken identity link between a patient and their autologous cell therapy from apheresis collection to infusion — distinct from Chain of Custody.

ISBT 128

The global standard for identification, coding, and labelling of Medical Products of Human Origin — blood components, cellular therapy products, tissue allografts, ocular tissue, and donor milk.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

Cellular therapy QMS

FACT-JACIE 9th edition QM Plan with live indicators.

Chain of identity

Barcode-verified at every handoff.

Indicator trends

12-month trend story built from operational data.

Industries this hits hardest

Blood & tissue

Frequently asked

Is FACT-JACIE accreditation legally required?

No — accreditation is voluntary. It is practically required by transplant networks (NMDP, WMDA), most payers and most commercial CAR-T sponsors as a condition of treating their products. Programmes without accreditation are progressively excluded from these networks.

How does FACT-JACIE relate to 21 CFR 1271?

FACT-JACIE is the accreditation overlay; 21 CFR 1271 (US) or Directive 2004/23/EC (EU) is the regulatory floor. A compliant programme implements both. The cellular therapy product itself may also be a 21 CFR 351/Annex 1 biologic with separate GMP requirements at the manufacturing site.

Do we need separate accreditation for clinical, collection and processing?

FACT-JACIE accredits the integrated programme — clinical, collection, processing — under one accreditation. Each component must satisfy the relevant Standards, but the accreditation is single. A programme that outsources processing must demonstrate equivalent oversight of the processing partner.

How long is FACT-JACIE accreditation valid?

Three years, with mid-cycle indicator submissions. Re-accreditation requires a full inspection cycle. The 9th edition delta closure is required at the next inspection regardless of where in the cycle a programme sits.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →